VTWG - ETF AI Analysis
Top Page
Vanguard Russell 2000 Growth ETF (VTWG)
VTWG’s rating reflects a mix of promising growth names and some higher-risk holdings in the small-cap growth space. Strong contributors like Krystal Biotech, with robust financial performance and successful international expansion, and Moog, with solid aerospace and defense growth, help support the fund’s quality. However, weaker holdings such as Twist Bioscience, which faces profitability and cash flow challenges and a bearish technical trend, along with several companies showing high leverage or overbought conditions, highlight the main risk: exposure to less-profitable, volatile growth stocks that can weigh on overall stability.
VTWG vs. SPDR S&P 500 ETF (SPY)
- AUM
- 1.41B
- Region
- North America
- Expense Ratio
- 0.06%
- Beta
- 1.20
- Issuer
- Vanguard
- Inception Date
- Sep 20, 2010
- Dividend Yield
- 0.69%
- Asset Class
- Equity
- Index Tracked
- Russell 2000 Growth Benchmark
VTWG Summary
VTWG is the Vanguard Russell 2000 Growth ETF, which follows the Russell 2000 Growth Index, a group of smaller U.S. companies expected to grow faster than average. It mainly holds small, innovative businesses in health care, technology, and industrials, including names like Twist Bioscience and JFrog. Someone might invest in VTWG to seek long-term growth and to diversify beyond large, well-known companies. However, because it focuses on small, fast-growing firms, the price can be more volatile and may go up and down sharply with changes in the market.
How much will it cost me?
This ETF has an expense ratio of 0.06%, which means you’ll pay about $0.60 per year for every $1,000 invested. That’s lower than the average ETF because it’s a passively managed fund that simply tracks the Russell 2000 Growth Index instead of paying managers to pick individual stocks.
What would affect this ETF?
VTWG could benefit if the U.S. economy stays healthy, innovation in areas like health care and technology continues, and investor appetite for smaller, fast-growing companies remains strong, especially in its key sectors. On the other hand, rising interest rates, economic slowdowns that hit small businesses harder, or tighter regulations in health care and tech could weigh on the fund’s growth-focused U.S. holdings and increase volatility.
VTWG Top 10 Holdings
VTWG is leaning heavily into U.S. small-cap health care and tech, and that’s where the story really unfolds. Glaukos has been a standout, rising on strong sales momentum, while JFrog and Protagonist Therapeutics add steady tech and biotech tailwinds. On the flip side, Moog and FirstCash have been lagging lately, acting like small anchors on the fund’s progress. Twist Bioscience and 10x Genomics show mixed but improving trends, reflecting the fund’s bet on innovative, higher-risk names that can swing performance sharply in either direction.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 TWST | Twist Bioscience | 0.83% | $13.95M | $10.06B | 292.34% | 43Neutral |
 MOG.A | Moog | 0.71% | $11.91M | $11.10B | 74.10% | 73Outperform |
 FROG | JFrog | 0.69% | $11.54M | $11.64B | 79.25% | 73Outperform |
 TXG | 10x Genomics | 0.69% | $11.53M | $9.13B | 351.83% | 60Neutral |
 BTSG | BrightSpring Health Services, Inc. | 0.62% | $10.39M | $13.24B | 100.48% | 67Neutral |
 GKOS | Glaukos | 0.62% | $10.32M | $14.07B | 170.93% | 61Neutral |
 KRYS | Krystal Biotech | 0.57% | $9.47M | $9.84B | 49.82% | 80Outperform |
 PTGX | Protagonist Therapeutics | 0.57% | $9.45M | $9.37B | 77.27% | 68Neutral |
 FCFS | FirstCash | 0.56% | $9.38M | $7.77B | 22.21% | 74Outperform |
 IDCC | InterDigital | 0.56% | $9.28M | $8.02B | -12.71% | 76Outperform |
VTWG Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For VTWG, the sentiment is Negative. The current price of 254.47 is below the 20-day moving average (MA) of 255.92, below the 50-day MA of 263.76, and below the 200-day MA of 261.39, indicating a bearish trend. The MACD of -1.80 indicates Negative momentum. The RSI at 44.46 is Neutral, neither overbought nor oversold. The STOCH value of 57.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for VTWG.
VTWG Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| VTWG | $254.47 | $270.00(6.10% Upside) | $1.41B | 0.06% | 61Neutral |
 IWO | $348.80 | $496.84(42.44% Upside) | $13.94B | 0.24% | 62Neutral |
 IJT | $165.26 | $205.57(24.39% Upside) | $7.45B | 0.18% | 68Neutral |
 SLYG | $110.29 | $137.61(24.77% Upside) | $4.77B | 0.15% | 68Neutral |
 FYC | $112.85 | $151.14(33.93% Upside) | $1.35B | 0.70% | 61Neutral |
 VIOG | $142.33 | $177.96(25.03% Upside) | $1.05B | 0.10% | 68Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| VTWG | Vanguard Russell 2000 Growth ETF | 254.47 | 21.48 | 9.22% | |
| IWO | iShares Russell 2000 Growth ETF | 348.80 | 29.17 | 9.13% | |
| IJT | iShares S&P Small-Cap 600 Growth ETF | 165.26 | 28.25 | 20.62% | |
| SLYG | SPDR S&P 600 Small Cap Growth ETF | 110.29 | 18.83 | 20.59% | |
| FYC | First Trust Small Cap Growth AlphaDEX Fund | 112.85 | 20.26 | 21.88% | |
| VIOG | Vanguard S&P Small-Cap 600 Growth ETF | 142.33 | 24.42 | 20.71% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.